tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

KTTA Stock Latest News

Pasithea Therapeutics begins dosing cohort 2 in Phase 1 trial of PAS-004
The FlyPasithea Therapeutics begins dosing cohort 2 in Phase 1 trial of PAS-004
1M ago
KTTA
Pasithea Therapeutics to present cancer study data showing PAS-004 efficacy
PremiumThe Fly
Pasithea Therapeutics to present cancer study data showing PAS-004 efficacy
2M ago
KTTA
Pasithea completes initial dosing in first cohort of Phase 1 PAS-004 trial
PremiumThe Fly
Pasithea completes initial dosing in first cohort of Phase 1 PAS-004 trial
3M ago
KTTA
Pasithea Therapeutics Corp trading resumes
PremiumThe Fly
Pasithea Therapeutics Corp trading resumes
5M ago
KTTA
Pasithea Therapeutics Corp trading halted, volatility trading pause
PremiumThe Fly
Pasithea Therapeutics Corp trading halted, volatility trading pause
5M ago
KTTA
Pasithea Therapeutics opens enrollment in the U.S. for Phase 1 trial of PAS-004
PremiumThe FlyPasithea Therapeutics opens enrollment in the U.S. for Phase 1 trial of PAS-004
5M ago
KTTA
Pasithea Therapeutics announces invention of crystalline form of PAS-004
PremiumThe Fly
Pasithea Therapeutics announces invention of crystalline form of PAS-004
7M ago
KTTA
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
PremiumPress Releases
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
7M ago
KTTA
Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004
PremiumThe Fly
Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004
7M ago
KTTA
Pasithea Therapeutics Corp trading halted, news pending
PremiumThe Fly
Pasithea Therapeutics Corp trading halted, news pending
7M ago
KTTA
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
PremiumPress Releases
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
7M ago
KTTA
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
PremiumPress Releases
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
7M ago
KTTA
Pasithea Therapeutics announces in vivo preclinical efficacy data for PAS-004
PremiumThe FlyPasithea Therapeutics announces in vivo preclinical efficacy data for PAS-004
8M ago
KTTA
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
PremiumPress Releases
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
8M ago
KTTA
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
PremiumPress Releases
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
8M ago
KTTA
Pasithea Therapeutics announces outcome of pre-IND meeting for PAS-004
PremiumThe Fly
Pasithea Therapeutics announces outcome of pre-IND meeting for PAS-004
8M ago
KTTA
Pasithea Therapeutics selects PAS-003 lead development candidate
PremiumThe Fly
Pasithea Therapeutics selects PAS-003 lead development candidate
9M ago
KTTA
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
PremiumPress Releases
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
10M ago
KTTA
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
PremiumPress Releases
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
11M ago
KTTA
Pasithea Therapeutics publishes study in PNAS on PAS-003
PremiumThe FlyPasithea Therapeutics publishes study in PNAS on PAS-003
12M ago
KTTA
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
PremiumPress Releases
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
12M ago
KTTA
Pasithea Therapeutics to commence $4M tender offer for common stock
PremiumThe Fly
Pasithea Therapeutics to commence $4M tender offer for common stock
1y ago
KTTA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >